← Issue №12/ week of Sep 20, 2026/Hepatology

An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).

From GI Signals issue №12: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology rct · n=286 · Sep 14, 2026 · Dig Liver Dis · IF 4.2

An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).

New therapyhepatocellular carcinoma
Clinical takeawayNo clinical action yet: a phase II/III trial in progress, awaiting efficacy and safety results.
What it foundPhase II/III trial testing GEMOX-based HAIC plus durvalumab/tremelimumab vs durvalumab/tremelimumab alone in advanced HCC with high tumor burden (Vp4 PVTT, Vp3 PVTT with bilateral involvement, >50% liver involvement).
ContextAddresses an unmet need in advanced HCC with high tumor burden, a population underrepresented in prior trials; HAIC has shown promise in Asian populations but lacks validation in Western cohorts.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Letissier O … Edeline J · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №12 Every paper GI Signals surfaces gets a page like this one. All issues